Lack of TB Drugs at Rajan Babu TB Hospital: HC closes PIL as Govt ensures supply

New Delhi: The Delhi High Court has concluded the proceedings on a Public Interest Litigation (PIL) concerning the alleged lack of medicines to treat TB patients at the MCD-run Rajan Babu Institute of Pulmonary Medicine and Tuberculosis.

 This decision followed assurances provided to a division bench comprising Acting Chief Justice Manmohan and Justice Manmeet PS Arora, indicating that the current medicine stock in Delhi would suffice for several weeks and additional supplies were on the way.

According to an IANS news report, The PIL, filed by NGO Social Jurist earlier this year, alleged that the sole ultrasound machine at the hospital was non-functional and that essential medicines had been unavailable for the past six months. Advocate Ashok Agarwal, representing the petitioner, argued that the shortage forced poor patients to buy medicines from outside sources.

Also Read:Delhi HC dismisses plea by MCD Paramedical staff challenging app-based attendance system

The Central government and the Mission Director of the Delhi State Health Mission submitted affidavits detailing the stock levels and the supply pipeline for essential drugs. These submissions confirmed that immediate shortages were being addressed effectively.

“Keeping in view the fact that the stock in hand of 4 FDC (A) drug is good for a month and for 3 FDC (A) drug is good for three weeks and rest of the supply is in the pipeline, the present petition is disposed of as satisfied,” the bench stated in its order.

Meanwhile, the Municipal Corporation of Delhi (MCD) assured the court that the ultrasound machine at the institute is now fully functional.

The court was informed that a CT scan machine was not required at the institute as patients below the poverty line were referred to Hindu Rao Hospital for free scans. Other patients could get scans at a nominal fee of Rs 1,500, typically covered by an NGO, news agency IANS reported.

Earlier, the Centre had assured the court of proactive measures to expedite the supply of anti-TB drugs to ensure uninterrupted patient care.

Also Read:No Salaries, No Drinking water: Delhi’s Hindu Rao, Rajan Babu doctors call off strike after Govt’s assurance

Powered by WPeMatico

NPPA Fixes Retail Price Of 37 Formulations, Details

New Delhi: Through a recent notice, the National Pharmaceutical Pricing Authority (NPPA) has fixed the retail price of the 37 formulations under the Drugs (Prices Control) Order.

This price fixation is followed by decisions made by the National Pharmaceuticals Pricing Authority (NPPA) at its 128th Authority Metting dated on 10th May 2024.

The list includes Akums Drugs and Pharmaceuticals, Abbott Healthcare’s Dapagliflozin, Metformin Hydrochloride (Extended Release) and Glimepiride Tablets, Mascot Health Series, Renon Healthcare’s Dapagliflozin, Metformin Hydrochloride and Glimepiride Tablets, Mascot Health Series, Primus Remedies’ Dapagliflozin, Metformin Hydrochloride (Extended Release) and Glimepiride Tablets.

The list further includes Pure and Cure Healthcare, Torrent Pharmaceuticals’ Telmisartan, Amlodipine, Hydrochlorothiazide Tablets, Akums Drugs and Pharmaceuticals, Sun Pharmaceuticals Industries’ Bilastine and Montelukast oral suspension, Intas Pharmaceuticals’ Antacid Antigas gel, Innova Captab, Dr. Reddy’s Laboratories’ Cefixime and Ofloxacin Oral suspension and etc.

This came exercise of the powers conferred by paragraphs 5, 11, and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May 2013 and S. O. 5249(E) dated 11th November 2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (NPPA), has fixed, the price as specified in column (6) of the table herein below as the retail price, exclusive of Goods and Services Tax, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said table with the strength, unit and name of manufacturer and marketing company, as specified in the corresponding entries in columns (3), (4) and (5) thereof;

Sl.

No.

Medicines

Strength

Unit

Manufacturer &

Marketing Company

Retail

Price (Rs.)

(1)

(2)

(3)

(4)

(5)

(6)

1

Dapagliflozin, Metformin Hydrochloride (Extended Release) and Glimepiride Tablets

Each film-coated bilayered Tablet contains: Dapagliflozin Propanediol USP eq. to Dapagliflozin 10mg Metformin Hydrochloride IP 1000mg (As Extended release) Glimepiride IP 1 mg

1 Tablet

M/s Mascot Health Series Pvt. Ltd. / M/s La Renon Healthcare Pvt. Ltd.

14.75

2

Dapagliflozin, Metformin Hydrochloride (Extended Release) and Glimepiride Tablets

Each film-coated bilayered Tablet contains: Dapagliflozin Propanediol USP eq. to Dapagliflozin 10mg Metformin Hydrochloride IP 1000mg (As Extended release) Glimepiride IP 1 mg

1 Tablet

M/s Mascot Health Series Pvt. Ltd. / M/s Primus Remedies Pvt. Ltd.

14.53

3

Dapagliflozin, Metformin Hydrochloride (Extended Release) and Glimepiride Tablets

Each film-coated bilayered Tablet contains: Dapagliflozin Propanediol USP eq. to Dapagliflozin 10mg

Metformin Hydrochloride IP 1000mg (As Extended release)

Glimepiride IP 1 mg

1 Tablet

M/s Akums Drugs & Pharmaceuticals Ltd. / M/s Abbott Healthcare Pvt.

Ltd.

14.75

4

Dapagliflozin, Metformin Hydrochloride

(Extended

Each film-coated bilayered Tablet contains:

1 Tablet

M/s Mascot Health Series Pvt. Ltd. / M/s La Renon

16.00

Sl.

No.

Medicines

Strength

Unit

Manufacturer & Marketing Company

Retail Price (Rs.)

(1)

(2)

(3)

(4)

(5)

(6)

Release) and Glimepiride Tablets

Dapagliflozin Propanediol USP eq. to Dapagliflozin 10mg

Metformin Hydrochloride IP 1000mg (As Extended release)

Glimepiride IP 2 mg

Healthcare Pvt. Ltd.

5

Dapagliflozin, Metformin Hydrochloride (Extended Release) and Glimepiride Tablets

Each film-coated bilayered Tablet contains: Dapagliflozin Propanediol USP eq. to Dapagliflozin 10mg

Metformin Hydrochloride IP 1000mg (As Extended release)

Glimepiride IP 2 mg

1 Tablet

M/s Mascot Health Series Pvt. Ltd. / M/s Primus Remedies Pvt. Ltd.

16.24

6

Dapagliflozin, Metformin Hydrochloride (Extended Release) and Glimepiride Tablets

Each film-coated bilayered Tablet contains: Dapagliflozin Propanediol USP eq. to Dapagliflozin 10mg

Metformin Hydrochloride IP 1000mg (As Extended release)

Glimepiride IP 2 mg

1 Tablet

M/s Akums Drugs & Pharmaceuticals Ltd. / M/s Abbott Healthcare Pvt.

Ltd.

16.43

7

Sitagliptin Phosphate, Metformin Hydrochloride, and Glimepiride Tablets

Each film coated Tablet contains:

Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 50mg

Metformin Hydrochloride IP 1000mg

Glimepiride IP 1 mg

1 Tablet

M/s Mascot Health Series Pvt. Ltd. / M/s Aristo Pharmaceuticals Pvt. Ltd.

13.35

8

Sitagliptin Phosphate, Metformin Hydrochloride and Glimepiride Tablets

Each film coated Tablet contains:

Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 50mg

Metformin Hydrochloride IP 1000mg

Glimepiride IP 2 mg

1 Tablet

M/s Mascot Health Series Pvt. Ltd. / M/s Aristo Pharmaceuticals Pvt. Ltd.

15.03

9

Dapagliflozin, Metformin Hydrochloride (Extended Release) and Glimepiride Tablets

Each film coated bilayered Tablet contains: Dapagliflozin Propanediol USP eq. to Dapagliflozin 10mg

Metformin Hydrochloride IP 500mg (As Extended release)

Glimepiride IP 1 mg

1 Tablet

M/s Mascot Health Series Pvt. Ltd. / M/s Primus Remedies Pvt. Ltd.

13.24

10

Dapagliflozin,

Metformin Hydrochloride

Each film coated bilayered Tablet contains:

Dapagliflozin Propanediol

1 Tablet

M/s Mascot Health Series Pvt. Ltd. /

14.83

Sl.

No.

Medicines

Strength

Unit

Manufacturer & Marketing Company

Retail Price (Rs.)

(1)

(2)

(3)

(4)

(5)

(6)

(Extended Release) and Glimepiride Tablets

USP eq. to Dapagliflozin 10mg

Metformin Hydrochloride IP 500mg (As Extended release)

Glimepiride IP 2 mg

M/s Primus Remedies Pvt. Ltd.

11

Diclofenac Diethylamine, Methyl Salicylate, Virgin Linseed Oil & Menthol Topical spray

Composition:

Diclofenac Diethylamine IP 1.16% w/w eq. to Diclofenac Sodium 1.00% w/w,

Methyl Salicylate IP 10.00% w/w,

Virgin Linseed Oil BP 3.0% w/w,

Menthol IP 5.00% w/w

1 gm

M/s Pontika Aerotech Limited / M/s Unison Pharmaceuticals Pvt. Ltd.

2.73

12

Povidone-Iodine & Ornidazole Ointment

Composition:

Povidone-Iodine IP 5%w/w (Available Iodine 0.5%w/w) Ornidazole IP 1% w/w in an Ointment base

1 gm

M/s Curetech Skincare / M/s J.B. Chemicals & Pharmaceuticals Ltd.

4.11

13

Bisoprolol Fumarate and Telmisartan Tablets

Each film coated Tablet contains:

Bisoprolol Fumarate IP 5 mg Telmisartan IP 40 mg

1 Tablet

M/s Ravenbhel Healthcare Pvt Ltd

/ M/s J.B. Chemicals & Pharmaceuticals

Ltd.

11.21

14

Bisoprolol Fumarate and Telmisartan Tablets

Each film coated Tablet contains:

Bisoprolol Fumarate IP 2.5 mg

Telmisartan IP 40 mg

1 Tablet

M/s Ravenbhel Healthcare Pvt Ltd

/ M/s J.B. Chemicals &

Pharmaceuticals Ltd.

9.65

15

Cefixime and Ofloxacin Oral suspension

Each 5ml reconstituted suspension contains: Cefixime IP as trihydrate eq. to Cefixime Anhydrous 50mg

Ofloxacin IP 50mg

1 ml

M/s Innova Captab Ltd. / M/s Emcure Pharmaceuticals Ltd.

1.90

16

Ibuprofen & Paracetamol Tablets

Each uncoated Tablet contains:

Ibuprofen IP 400mg Paracetamol IP 325mg

1 Tablet

M/s Prochem Pharmaceuticals Pvt. Ltd. / M/s Softdeal Pharmaceuticals

Private Limited

1.59

17

Ranitidine Hydrochloride, Dicyclomine Hydrochloride & Activated Simethicone Tablet

Each film coated Tablet contains:

Ranitidine Hydrochloride IP eq. to Ranitidine 150mg Dicyclomine Hydrochloride IP 10mg

Activated Dimethicone IP

(Simethicone) 20mg

1 Tablet

M/s IndocoRemedies Limited

2.09

18

Telmisartan,

Amlodipine &

Each film coated Tablet

contains:

1 Tablet

M/s Pure and Cure

Healthcare Pvt.

15.96

Sl.

No.

Medicines

Strength

Unit

Manufacturer & Marketing Company

Retail Price (Rs.)

(1)

(2)

(3)

(4)

(5)

(6)

Hydrochlorothia zide Tablets

Telmisartan IP 80mg, Amlodipine Besilate IP eq. to Amlodipine 5mg Hydrochlorothiazide IP 12.50mg

Ltd. / M/s Torrent Pharmaceuticals Ltd.

19

Telmisartan, Amlodipine & Hydrochlorothia zide Tablets

Each film coated Tablet contains:

Telmisartan IP 40mg,Amlodipine Besilate IP eq. to Amlodipine 5mgHydrochlorothiazide IP

12.50mg

1 Tablet

M/s Pure and Cure Healthcare Pvt.

Ltd. / M/s Torrent Pharmaceuticals Ltd.

10.45

20

Ceftazidime and Avibactam (As Sodium Salt) powder for concentrate for solution for infusion

Each vial contains: Ceftazidime Pentahydrate (Sterile) eq. to Ceftazidime IP 2.0gm

Avibactam Sodium (Sterile) eq. to Avibactam 0.5gm Sterile Sodium Carbonate IP (anhydrous) 232.9mg

Sodium per vial content 6.44 mmol eq. to 148mg

1 Vial

M/s Aqua Vitoe Laboratories / M/s Emcure Pharmaceuticals Limited

1569.9

4

21

Glimepiride & Metformin Hydrochloride (ER) Tablets

Each uncoated bilayered Tablet contains: Glimepiride IP 4mg Metformin Hydrochloride IP

500mg (In extended-release form)

1 Tablet

M/s Innova Captab Ltd. / M/s Cadila Pharmaceuticals Ltd.

11.28

22

Glimepiride & Metformin Hydrochloride (ER) Tablets

Each uncoated bilayered Tablet contains: Glimepiride IP 3mg Metformin Hydrochloride IP

500mg (In extended-release form)

1 Tablet

M/s Innova Captab Ltd. / M/s Cadila Pharmaceuticals Ltd.

9.84

23

Bilastine and Montelukast oral suspension

Each 5ml suspension contains:

Bilastine 10mg Montelukast Sodium IP eq. to Monelukast 4mg

1 ml

M/s Akums Drugs & Pharmaceuticals Ltd. / M/s Sun Pharmaceuticals

Industries Limited

1.72

24

Aceclofenac, Paracetamol & Thiocolchicoside Tablets

Each film coated Tablet contains:

Aceclofenac IP 100mg Paracetamol IP 325mg Thiocolchicoside IP 8mg

1 Tablet

M/s Innova Captab Ltd. / M/s Mankind Pharma Ltd.

25.98

25

Aceclofenac, Paracetamol & Thiocolchicoside Tablets

Each film coated Tablet contains:

Aceclofenac IP 100mg Paracetamol IP 325mg Thiocolchicoside IP 4mg

1 Tablet

M/s Innova Captab Ltd. / M/s Mankind Pharma Ltd.

18.05

26

Hydrocortisone Acetate, Lidocaine, Zinc Oxide &

Each suppository contains: Hydrocortisone Acetate IP 0.25% w/w Lidocaine USP 3.0% w/w

1

Supposi tory

M/s Bliss GVS Pharma Ltd. / M/s Zydus Healthcare

Limited

14.30

Sl.

No.

Medicines

Strength

Unit

Manufacturer & Marketing Company

Retail Price (Rs.)

(1)

(2)

(3)

(4)

(5)

(6)

Allantoin Suppositories

Zinc Oxide IP 5.0% w/w Allantoin IP 0.5% w/w

27

Ciprofloxacin & Tinidazole Tablet

Each film coated Tablet contains:

Ciprofloxacin Hydrochloride IP eq. to Ciprofloxacin 500mg

Tinidazole IP 600mg

1 Tablet

M/s Aagya Biotech Pvt. Ltd. / M/s J. B. Chemicals & Pharmaceuticals Ltd.

10.64

28

Fexofenadine Hydrochloride & Montelukast Tablet

Each film coated Tablet contains:

Fexofenadine Hydrochloride IP 120mg

Montelukast Sodium IP eq. to

Montelukast 10mg

1 Tablet

M/s Aagya Biotech Pvt. Ltd. / M/s J. B. Chemicals & Pharmaceuticals Ltd.

15.10

29

Antacid Antigas gel

Each 10ml (two teaspoonful) contains: Dried Aluminium Hydroxide Gel IP (added as paste) 830mg

Magnesium Hydroxide IP (added as paste) 185mg Sodium Carboxymethylcellulose IP 100mg

Simethicone IP 50mg

1 ml

M/s Intas Pharmaceuticals Pvt. Ltd.

0.56

30

Bisoprolol Fumarate and Amlodipine Tablets

Each film coated Tablet contains:

Bisoprolol Fumarate IP 2.5mg

Amlodipine Besylate IP Eq.

to Amlodipine 5mg

1 Tablet

M/s Savi Health Science / M/s Alkem Laboratories Ltd.

6.40

31

Bisoprolol Fumarate and Amlodipine Tablets

Each film coated Tablet contains:

Bisoprolol Fumarate IP 5mg Amlodipine Besylate IP Eq.

to Amlodipine 5mg

1 Tablet

M/s Savi Health Science / M/s Alkem Laboratories Ltd.

8.98

32

Atorvastatin, Clopidogrel & Aspirin Capsule

Each hard gelatine capsule contains:

Atorvastatin Calcium IP eq. to Atorvastatin 40mg (As green coloured pellets), Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (As two reddish brown coloured film coated Tablet, each containg 37.5mg Clopidogrel Tablets IP),

Aspirin IP 75mg (As enteric coated white-coloured

pellets)

1

Capsule

M/s Windlas Biotech Limited / M/s Aristo Pharmaceuticals Pvt. Ltd.

13.84

33

Levocetirizine Dihydrochloride & Montelukast

Each 5ml contains: Levocetirizine Dihydrochloride IP 2.5mg

1 ml

M/s Aagya Biotech

/ M/s J. B. Chemicals &

1.47

Sl.

No.

Medicines

Strength

Unit

Manufacturer & Marketing Company

Retail Price (Rs.)

(1)

(2)

(3)

(4)

(5)

(6)

Sodium suspension

Montelukast Sodium IP eq. to Montelukast 4mg

Pharmaceuticals Ltd.

34

Linagliptin & Metformin Hydrochloride (ER) Tablets

Each film coated bilayered Tablet contains: Linagliptin 5mg

Metformin Hydrochloride IP 500mg (as extended-release

form)

1 Tablet

M/s Mascot Health Series Pvt. Ltd. / M/s Mankind Pharma Limited

12.86

35

Pantoprazole & Domperidone Tablet

Each gastro-resistant Tablet contains: Pantoprazole Sodium IP (as sesquihydrate) eq. to Pantoprazole 40mg

Domperidone IP 10mg

1 Tablet

M/s Innova Captab Ltd. / Dr. Reddy’s Laboratories Limited

7.24

36

Chlorphenirami ne Maleate, Dextromethorph an & Phenylephrine Syrup

Each 5ml contains: Chlorpheniramine Maleate IP 2mg

Phenylephrine Hydrochloride IP 5mg Dextromethorphan

Hydrobromide IP 10mg

1 ml

M/s Stedman Pharmaceuticals Pvt. Ltd.

1.02

37

Cefixime and Ofloxacin Oral suspension

Each 5ml reconstituted suspension contains: Cefixime IP as trihydrate eq. to Cefixime Anhydrous 50mg Ofloxacin IP 50mg

1 ml

M/s Innova Captab Ltd. / Dr. Reddy’s Laboratories Limited

1.90

The notification further added:

  • The manufacturer of the above-mentioned formulations i.e., “new drug” under paragraph 2(1)(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove.
  • The manufacturer may add Goods and Services Tax only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above-said table.
  • The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form–V from the date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.
  • As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.
  • The above-mentioned retail price is applicable only to the individual manufacturer/marketer as mentioned above i.e. who have applied for the same by submitting Form-I for price fixation/revision as stipulated under DPCO, 2013 and subject to fulfilment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturer/marketing companies.
  • In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.
  • Consequent to the fixation of retail price of such formulation as specified in column (2) of the above table with the strength and name of Manufacturer & Marketing Companies specified in the corresponding entries in Column (3) & (5) thereof, the price order(s) fixing the retail price of the formulation with specified strength for that Manufacturer & Marketing Companies as specified in corresponding entries in Column (2), (3) and (5) thereof, if any, issued prior to this notification, stand(s) superseded.

To view the notice, click the link below:

https://medicaldialogues.in/pdf_upload/retailprice37-238779.pdf

Also Read: NPPA Fixes Retail Prices of 69 Formulations, Details

Powered by WPeMatico

Govt Hospital doctor treats patient under mobile flashlight amid power cut

A doctor at the government hospital in the Molakalmuru taluk in Chitradurga district treated a patient under the flashlight of a mobile phone after a prolonged power cut. The incident was captured on camera and was shared on social media.
According to sources, the area has been affected by power cuts for the past one week and the hospital is no exception.
For more information click on the link below:

Powered by WPeMatico

Junior doctor death, family alleges harassment by professors

The death of a 26-year-old junior doctor by suicide at a college hostel in Dehradun has triggered massive uproar in Uttarakhand. The paediatric student from Shri Guru Ram Rai Institute of Medical and Health Sciences was found dead in his hostel room on May 17. His family and friends launched a social media campaign, alleging harassment by professors and long working hours led to his suicide.
According to India Today, the student’s thesis was recently rejected by a professor. His father accused the college’s management committee and three individuals specifically, resulting in an FIR against Dr. Utkarsh Sharma, head of the Paediatrics department, and professors Ashish Sethi and Bindu Agarwal under section 306 of the IPC.

Powered by WPeMatico

NIA searches residences of 2 Coimbatore-based doctors in Rameshwaram Cafe blast case

The National Investigation Agency (NIA) searched the residences of two Coimbatore-based doctors in Tamil Nadu in connection with the blast at the Rameshwaram Cafe in Bengaluru on March 1.
According to the investigating agency sources, the raids were connected to the blast at the Rameshwaram Cafe in Bengaluru on March 1. A low-intensity IED bomb had exploded at the cafe injuring 10 people.
For more information click on the link below:

Powered by WPeMatico

Health Bulletin 24/ May/ 2024

Here are the top health stories for the day:

Even home-made foods can be unhealthy, according to ICMR
Home-cooked meals, often considered healthier, can still be unhealthy if they contain too much fat, sugar, or salt. According to the Indian Council of Medical Research (ICMR), even homemade foods can become unhealthy when prepared with high amounts of these ingredients. High-fat foods are energy-dense, meaning they have high calories but lack essential nutrients like vitamins, minerals, and fiber. Regular consumption of such foods can lead to overweight and obesity, depriving the body of necessary nutrients.
High sugar content in foods, including store-bought items like juices and cereals, can contribute to obesity, type 2 diabetes, oral defects, and abnormal blood sugar levels. Excessive sugar intake is a major factor in significant weight gain and related health issues. Indian food is also known for its high salt usage, which can increase sodium intake. Long-term consumption of a high-salt diet can raise blood pressure, leading to heart attacks, strokes, and kidney failure, especially in individuals with hypertension.
Rameshwaram cafe blast case: Two Coimbatore doctors questioned by NIA
The National Investigation Agency (NIA) searched the residences of two Coimbatore-based doctors in Tamil Nadu in connection with the blast at the Rameshwaram Cafe in Bengaluru on March 1.
According to the investigating agency sources, the raids were connected to the blast at the Rameshwaram Cafe in Bengaluru on March 1. A low-intensity IED bomb had exploded at the cafe injuring 10 people.
For more information, click on the link below:

Uttarakhand: Junior doctor’s suicide at medical college sparks harassment charges
The death of a 26-year-old junior doctor by suicide at a college hostel in Dehradun has triggered massive uproar in Uttarakhand. The paediatric student from Shri Guru Ram Rai Institute of Medical and Health Sciences was found dead in his hostel room on May 17. His family and friends launched a social media campaign, alleging harassment by professors and long working hours led to his suicide.
According to India Today, the student’s thesis was recently rejected by a professor. His father accused the college’s management committee and three individuals specifically, resulting in an FIR against Dr. Utkarsh Sharma, head of the Paediatrics department, and professors Ashish Sethi and Bindu Agarwal under section 306 of the IPC.
Karnataka: Doctor treat patient under mobile flashlight amid power cut
A doctor at the government hospital in the Molakalmuru taluk in Chitradurga district treated a patient under the flashlight of a mobile phone after a prolonged power cut. The incident was captured on camera and was shared on social media.
According to sources, the area has been affected by power cuts for the past one week and the hospital is no exception.
For more information, click on the link below:

Powered by WPeMatico

Over 750,000 antimicrobial resistance deaths preventable yearly via vaccines, water, sanitation and infection control

Speaking at the World Health Assembly, authors of a new Lancet Series call for urgent global action on antimicrobial resistance (AMR).

Powered by WPeMatico

Poor access to essential surgery is costing lives, says study

Inadequate access to simple elective surgery in developing countries is storing up future health problems for patients and may create a spiral of future health complications putting more people’s lives at risk, a new study reveals.

Powered by WPeMatico

UK review on gender medicine ‘largely ignored’ in the US, finds journalist

The newly released Cass Review on transgender care for young people has been pivotal in the UK, where the prescription of puberty “blocking” drugs outside research protocols has now ceased.

Powered by WPeMatico

Quantitative imaging reveals collagen changes in melanoma tumors during immunotherapy

Collagen, a major component of the extracellular matrix, plays a crucial role in tumor development. During the development of tumors (“tumorigenesis”), collagen fibers become linearized and densely deposited, hindering immune cell infiltration and promoting tumor metastasis. However, quantifying these collagen changes during melanoma progression has been challenging.

Powered by WPeMatico